A multi-center, randomized, double blind, dose escalating phase III study on the efficacy, safety and long term outcome of continuous vs. on demand treatment of chronic spontaneous urticaria with rupatadine

Trial Profile

A multi-center, randomized, double blind, dose escalating phase III study on the efficacy, safety and long term outcome of continuous vs. on demand treatment of chronic spontaneous urticaria with rupatadine

Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Jan 2018

At a glance

  • Drugs Rupatadine (Primary)
  • Indications Urticaria
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jan 2018 Status changed from recruiting to discontinued.
    • 09 Sep 2016 Planned End Date changed from 1 Apr 2016 to 1 Jun 2017.
    • 09 Sep 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top